Europe GMP approval for Shilpa Medicare Unit 4 in Jadcherla, Telangana

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹1025.70

prior close

₹1045.00

announcement price

After-mkt

timing

Nifty Microcap 250market+0.8%-2.0% vs market

Pharmaceuticals peers, median of 167sector-0.1%-1.0% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-1.7

15m

-0.4

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1+0.8-2.0-0.1-1.0

Next day

-5.2+1.0-6.2-0.1-5.0

-6.3+1.7-8.0-0.2-6.0

-9.8+0.1-9.9-0.9-8.9

-8.4+0.8-9.1-0.7-7.6

-15.2-0.9-14.3-2.2-13.1

-16.1-4.5-11.6-4.4-11.6

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Medicare has received GMP certification from AGES, Austria for its Unit 4 in Jadcherla, Telangana after a successful inspection from 27-30 July 2026. The unit manufactures sterile injections and non-sterile tablets and capsules for European and global markets. This facility-level certification enables the company to supply products to Europe and supports future export growth.

Likely market impact

Positive: enables supply of sterile injections and other dosage forms to European markets and supports future export revenue growth.